DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2004/0266836A1 Buhlmayer Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2004/0266836A1 Buhlmayer Et Al US 2004O266836A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0266836A1 Buhlmayer et al. (43) Pub. Date: Dec. 30, 2004 (54) ORGANIC COMPOUNDS Related U.S. Application Data (76) Inventors: Peter Buhlmayer, Arlesheim (CH); (60) Provisional application No. 60/330,337, filed on Oct. Randy Lee Webb, Flemington, NJ 18, 2001. (US)US Publication Classification Correspondence Address: (51) Int. Cl." ..................... A61K 31/455; CO7D 213/46; NOVARTS CO7D 211/82 CORPORATE INTELLECTUAL PROPERTY (52) U.S. Cl 514/355; 54.6/315 ONE HEALTH PLAZA 430/2 Oa - 1 - O - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - s EAST HANOVER, NJ 07936-1080 (US) (57) ABSTRACT The invention relates to a salt formed of at least one (21) Appl. No.: 10/493,040 AT-receptor antagonist having at least one acidic center and of at least one cardiovascular ingredient having at least one (22) PCT Filed: Oct. 17, 2002 basic center that can be used for treating cardiovascular diseases and conditions, their prophylaxis or delay of pro (86) PCT No.: PCT/EP02/11652 gression. US 2004/0266836 A1 Dec. 30, 2004 ORGANIC COMPOUNDS 0007. The term “basic center” whenever referred hereinto means a functional group able to gain a proton, for example, 0001. This invention relates to salts formed of an AT the basic amino function in e.g. alkylamines, Such as ??, or receptor antagonist and a cardiovascular ingredient, phar any basic heterocycles, Such as pyridines, pyrazines, or maceutical compositions thereof and methods of using Said piperidines. Salts to treat patients Suffering from cardiovascular diseases and related conditions. 0008. The term “patient” whenever referred to herein 0002. As cardiovascular diseases are leading causes of means mammals including humans. death in industrialised countries and as the majority of 0009. The term “additive effect” or “synergistic effect”, affected patients are middle aged, there exists an increasing respectively, whenever referred to herein, for example, may need for potent as well as easily administered drugs for the be defined using the following equations: therapy of cardiovascular diseases. Under the term cardio vascular diseases and related conditions commonly used in afA+b/B=1 means an additive effect the art as a generic term may be Summarized diseases or afA+b/B-1 means a synergistic or superadditive effect, conditions Such as e. g. hypertension, congestive heart failure, post myocardial infarction, angina pectoris, coronary 0010 where “A” and “B” are equieffective doses of the heart diseases, cardiac arrhythmia, atherosclerosis, endothe individual ingredients when each is present alone, “a” and lial dysfunction, renal diseases, e.g. acute and preferably “b' are the respective doses in the Salt according to the chronic renal disease, isolated Systolic hypertension, periph invention that give the effect level achieved by dose “A” eral vascular disease, hyperlipidemia, Stroke or end-organ alone or dose “B” alone. Reference is made to R.J. Tallarida. damage. Although drug classes as well as their combinations "Statistical analysis of drug combinations for Synergism', for the treatment of Said diseases and related conditions are Pain 1992; 49:93-97 and “Drug synergism and dose-effect well known and commonly used, the patient compliance is data analysis”, Editor, R. J. Tallarida, Chapman and Hall/ often reduced due to the complex therapeutic Schemes and CRC, New York, 2000. the high intake rates. 0011. It is expected that in the case of the salts according 0003. The present invention provides a unique concept, to the invention, effects will be assessed e.g. as changes in which is an alternative to fixed combinations. For the first blood pressure and more specifically, as antihypertensive time, combination salts of at least one AT receptor antago effects. Therefore, the two ingredients forming a Salt accord nist with at least one further basic cardiovascular active ing to the invention would be synergistic when their effects principle (ingredient) have been made. In a fixed combina are greater than that expected from the Sum of the individual tion, different active principles are Separately combined in a ingredients, especially at the same doses as in the Salt. The dosage unit form. In a conventional fixed combination, hypothesis to be tested is that the two active ingredients are acidic or basic active ingredients may react within the additive when given together. If they are not additive, then dosage unit form with pharmaceutical auxiliaries and addi an interaction has occurred that may result e.g. in a Super tives, e.g. by forming esters and the like. A prolonged additive response. With a careful experimental design, this Storage of corresponding dosage unit forms may result in an can be assessed using appropriate Statistical methods as increased amount of Side products. A dosage unit form referenced above, e.g. corresponding effects can be taken comprising a combination Salt formed of at least two active from dose-response-curves. principles is more stable and resistant to forming unwanted 0012. In addition to blood pressure, the measurements of Side products. Furthermore, combination Salts according to heart rate or neurohormones (plasma renin activity, aldos the present invention have improved properties. Corre terone or norepinephrine) may also be used to determine the sponding improved properties comprise Suitable and relationship between the Salt and their individual component improved therapeutic activities and pharmacodynamic drugs. effects. For example, the beneficial effects of a combination Salt formed of at least two active principles comprises a 0013 Finally, the determination of plasma levels of each broader therapeutic applicability, a potentiation or Syner component of the Salt can also be used to indicate a response, gism of the activity of one of the Salt components, an for example, additive or Synergistic, that is different from enhancement of the pharmacodynamic properties. A com that of the component parts. It is understood that a direct bination Salt can also be used to achieve therapeutic effects relationship exists between the amount of drug in the plasma even at Sub-therapeutic amounts of at least one active and the pharmacologic effect induced by the drug. There principle within a corresponding combination Salt. fore, drug levels of the component drugs contained within 0004. Accordingly, the invention provides salts formed of the Salt can be used, either alone or in conjunction with the at least one AT-receptor antagonist having at least one pharmacodynamic response to demonstrate an advantage of acidic center and of at least one cardiovascular ingredient the salt formulation over that of individual components of having at least one basic center. the Salt. 0014. The term “potentiation” shall mean an enhance 0005. The term “at least one” whenever referred to herein ment of a corresponding pharmacological activity or thera may define one, two or more units. peutic effect, respectively. Potentiation of one component 0006. The term “acidic center” whenever referred to within the combination Salt according to the present inven herein means a functional group able to split of a proton e.g. tion formed with another component within the combination the hydrogen atom of the carboxyl group, of the Sulphona Salt according to the present invention means that an effect mide group or that of the tetrazole ring of the AT-receptor is being achieved that is greater than that achieved with one antagonist. component alone. US 2004/0266836 A1 Dec. 30, 2004 0015 The term “synergistic effect” or “effect of “poten in EP 678503 and incorporated herein by reference. Espe tiation' is used in the context of this application to mean an cially preferred is the hemi-fumarate Salt thereof. enhanced responsiveness to the drug. For example, if the Salts according to the invention result in an improvement in 0023 Beta-blockers are known in the art. A beta blocker the absorption, with an increase in the plasma concentration preferably is a representative Selected from the group con of the AT-receptor blocker then the extent of e.g. blood Sisting of a Selective B1-blocker, Such as atenolol, bisoprolol preSSure lowering may be “potentiated” or greater than (especially the fumarate thereof), metoprolol (especially the hemi-(R,R)fumarate or fumarate thereof), furthermore, ace expected. butolol (especially the hydrochloride thereof), esmolol 0016. The pharmacodynamic properties of one active (especially the hydrochloride thereof), celiproplol (espe principle within the combination Salt of the present inven cially the hydrochloride thereof), taliprolol, or acebutolol tion can also be potentiated by the further active principle (especially the hydrochloride thereof), a non-Selective within the combination Salt of the present invention leading f-blocker, Such as Oxprenolol (especially the hydrochloride to Synergism or potentiation. thereof), pindolol, furthermore, propanolol (especially the hydrochloride thereof), bupranolol (especially the hydro 0017. The term “AT-receptor antagonist” (also called chloride thereof), penbutolol (especially the Sulphate Angiotensin-II-receptor antagonist) whenever referred here thereof), mepindolol (especially the Sulphate thereof), car into has to be understood to define those active ingredients teolol (especially the hydrochloride thereof) or nadolol, and that bind to the AT-receptor subtype of Angiotensin-II but a B-blocker with C-blocking
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • WO 2011/089216 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date t 28 July 2011 (28.07.2011) WO 2011/089216 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) C07K 1/13 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 1/1 07 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/050821 HN, HR, HU, ID, J , IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 2 1 January 201 1 (21 .01 .201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1015 1465. 1 22 January 2010 (22.01 .2010) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): AS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, CENDIS PHARMA AS [DK/DK]; Tuborg Boulevard TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 12, DK-2900 Hellerup (DK).
    [Show full text]
  • Multimedia Appendix 1. Search Strategy Developed for Medline Via Ovid to Identify Existing Systematics Review. Concept 1: BP
    Multimedia Appendix 1. Search strategy developed for Medline via Ovid to identify existing systematics review. Concept 1: BP lowering regimens 1 exp antihypertensive agents/ 2 (antihypertensive$ adj (agent$ or drug)).tw. 3 exp thiazides/ 4 (chlorothiazide or benzothiadiazine or bendroflumethiazide or cyclopenthiazide or metolazone or xipamide or hydrochlorothiazide or hydroflumethiazide or methyclothiazide or polythiazide or trichlormethiazide or thiazide?).tw. 5 (chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or oxodolin or thalitone or hygroton or indapamide or metindamide).tw. 6 ((loop or ceiling) adj diuretic?).tw. 7 (bumetanide or furosemide or torasemide).tw. 8 exp sodium potassium chloride symporter inhibitors/ 9 (eplerenone or amiloride or spironolactone or triamterene).tw. 10 or/1-9 11 exp angiotensin-converting enzyme inhibitors/ 12 ((angiotensin$ or kininase ii or dipeptidyl$) adj3 (convert$ or enzyme or inhibit$ or recept$)).tw. 13 (ace adj3 inhibit$).tw. 14 acei.tw. 15 exp enalapril/ 16 (alacepril or altiopril or benazepril or captopril or ceronapril or cilazapril or delapril or enalapril or fosinopril or idapril or imidapril or lisinopril or moexipril or moveltipril or pentopril or perindopril or quinapril or ramipril or spirapril or temocapril or trandolapril or zofenopril or teprotide).tw. 17 or/11-16 18 exp Angiotensin II Type 1 Receptor Blockers/ 19 (angiotensin$ adj4 receptor$ adj3 (antagon$ or block$)).tw. 20 exp losartan/ 21 (KT3-671 or candesartan or eprosartan or irbesartan or losartan or
    [Show full text]
  • Příloha K Vyhlášce Č. 57/1997 Sb. Léčivé Přípravky Plně Hrazené Ze
    Příloha k vyhlášce č. 57/1997 Sb. Léčivé přípravky plně hrazené ze zdravotního pojištění a výše úhrad jednotlivých léčivých látek ODDÍL A Léčivé přípravky plně hrazené ze zdravotního pojištění jsou v seznamu léčivých přípravků plně hrazených ze zdravotního pojištění a v přehledu jednotlivých léčivých látek s výší jejich úhrad (dále jen „seznam“) označeny jejich kódem a názvem s uvedením lékové formy a velikosti balení. Výše úhrady jednotlivých léčivých látek v korunách za uvedené jednotkové množství těchto léčivých látek je stanovena v sedmém sloupci příslušných řádků seznamu. V seznamu mají použité zkratky tento význam a) způsob podání (aplikace) inhal. inhalační aplikační formy (spraye, prášky a roztoky k inhalaci) intraderm. aplikační cesta některých alergenů (nitrokožně) lok. lokální (zevní) aplikační formy parent. injekční aplikační formy (injekce, suché injekce, infúze) p.o. perorální aplikační formy (tablety, tobolky, dražé, potahované tablety) p.rect. rektální aplikační formy PRICK test k diagnostice subkut. aplikační cesta některých alergenů sublng. perorální aplikační formy pod jazyk (apikace do dutiny ústní) transd. transdermální (kožní) aplikační formy (náplasti) vag. vaginální (poševní) aplikační formy b) lékové formy LF lékové formy aer aerosol aer dos aerosol s dávkovačem cap kapsle, tobolka cap inh kapsle inhalační (inhaleta) cap ret kapsle retardovaná crm krém crm fett krém mastný crm vag krém vaginální drg dražé drg ret dražé retardované emp náplast enm enema, klyzma foa pěna gel gel gel oph gel oční gel vag gel vaginální
    [Show full text]
  • Supplemental Data
    DMD #48819 Supplemental Data Title: Application of Hybrid Approach Based on Empirical and Physiological Concept for Predicting Pharmacokinetics in Humans -Usefulness of Exponent on Prospective Evaluation of Predictability- Authors: Hiroyuki Sayama, Hiroshi Komura, Motohiro Kogayu Journal Title: Drug Metabolism and Disposition 1 DMD #48819 Supplemental Table 1 In vitro and in vivo data for allometric scaling of CL and Vss fup RB in vitro CLint (mL/min/kg) in vivo CL (mL/min/kg) in vivo Vss (mL/kg) Refference Human Human Human Dog Monkey Rabbit Rat Mouse Human Dog Monkey Rabbit Rat Mouse Human Dog Monkey Rabbit Rat Mouse Acivicin -- -- -- -- -- -- -- -- -- -- -- -- -- -- 580 500 600 -- 650 930 63 Alfentanil -- -- -- -- -- -- -- -- -- -- -- -- -- -- 800 953 -- 1069 975 -- 8 Amiodarone -- -- -- -- -- -- -- -- -- -- -- -- -- -- 66000 4600 5110 -- 72300 -- 23 Amlodipine -- -- -- -- -- -- -- -- -- -- -- -- -- -- 21000 25000 -- -- 32000 27000 101 Amphotericin B -- -- -- -- -- -- -- -- -- -- -- -- -- -- 4011 5025 -- 1855 2300 3121 85 Amsacrine -- -- -- -- -- -- -- -- -- -- -- -- -- -- 1560 2800 -- 1700 4500 7420 80 Antipyrine 1 1 0.28 3.95 -- 4.07 1.58 -- 0.62 a 8.18 a -- 7.32 a 3.53 a -- 584 a 738 a -- 903 a 657 a 720 5, 6, 12, 52, 76, 91, 118 Biperiden -- -- -- -- -- -- -- -- -- -- -- -- -- -- 6200 9500 3600 19300 14000 -- 23, 70 Bosentan -- -- 0.68 0.87 -- 15.89 5.71 7.91 2.00 1.3 -- 72 38.1 31.43 -- -- -- -- -- -- 49, 52 Caffeine 0.96 1 0.40 0.83 -- 1.18 2.55 -- 1.32 a 1.83 a -- 5.03 a 5.02 a -- 614 a 887 a 830 508 a 763 a 760 9, 10, 11, 17,
    [Show full text]
  • SUPPLEMENTARY MATERIAL 1: Search Strategy
    SUPPLEMENTARY MATERIAL 1: Search Strategy Medline search strategy 1. exp basal ganglia hemorrhage/ or intracranial hemorrhages/ or cerebral hemorrhage/ or intracranial hemorrhage, hypertensive/ or cerebrovascular disorders/ 2. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or pon$ or lentiform$ or brainstem or cortic$ or cortex$ or subcortic$ or subcortex$) adj5 (h?emorrhag$ or h?ematoma$ or bleed$)).tw 3. ((hemorrhag$ or haemorrhag$) adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw 4. (ICH or ICHs or PICH or PICHs).tw 5. 1 or 2 or 3 or 4 6. exp blood pressure/ 7. exp hypertension/ 8. (blood pressure or bloodpressure).tw 9. ((bp or blood pressure) adj5 (lowering or reduc$)).tw 10. ((strict$ or target$ or tight$ or intens$ or below) adj3 (blood pressure or systolic or diastolic or bp or level$)).tw 11. (hypertension or hypertensive).tw 12. ((manage$ or monitor$) adj3 (hypertension or blood pressure)).tw 13. ((intense or intensive or aggressive or accelerated or profound or radical or severe) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 14. ((standard or normal or ordinary or guideline or guide line or guideline recommend$ or recommend$ or convention$ or usual or established) adj5 ((bp or blood pressure) adj5 (lowering or reduc$ or decreas$ or decrement or dimin$ or declin$))).tw 15. (antihypertensive adj2 (agent$ or drug$ or medicat$)).tw 1 16. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 17.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,637,524 B2 Rao Et Al
    USOO8637524B2 (12) United States Patent (10) Patent No.: US 8,637,524 B2 Rao et al. (45) Date of Patent: Jan. 28, 2014 (54) PYRIMIDINONE INHIBITORS OF Tonn, Biological Mass Spectrometry vol. 22 Issue 11, pp. 633-642 LIPOPROTEIN-ASSOCATED (1993).* PHOSPHOLPASE A2 Hist Biomedical Spectrometry vol. 9 Issue 7, pp. 269-277 Wolen, Journal of Clinical Pharmacology 1986; 26: 419-424.* (75) Inventors: Tadimeti Rao, San Diego, CA (US); Browne, Journal of Clinical Pharmacology 1998; 38: 213-220.* Chengzhi Zhang, San Diego, CA (US) Baillie, Pharmacology Rev. 1981: 33:81-132.* Gouyette, Biomedical and Environmental Mass Spectrometry, vol. (73) Assignee: Auspex Pharmaceuticals, Inc, La Jolla, 15, 243-247 (1988).* CA (US) Cherrah, Biomedical and Environmental Mass Spectrometry vol. 14 Issue 11, pp. 653-657 (1987).* Pieniaszek, J. Clin Pharmacol. 1999; 39: 817-825.* (*) Notice: Subject to any disclaimer, the term of this Honma et al., Drug Metab Dispos 15 (4): 551 (1987).* patent is extended or adjusted under 35 Kushner, D. Jet al., Pharmacological uses and perspectives of heavy U.S.C. 154(b) by 58 days. water and deuterated compounds, Can. J. Physiol. Pharmacol. (1999), 77, 79-88. (21) Appl. No.: 12/840,725 Bauer et al., Influence of long-term infusions on lidocaine kinetics, Clin. Pharmacol. Ther. (1982), 31(4), 433-7. (22) Filed: Jul. 21, 2010 Borgstrom et al., Comparative Pharmacokinetics of Unlabeled and Deuterium-Labeled Terbutaline: Demonstration of a Small Isotope Effect, J Pharm. Sci., (1988), 77(11) 952-4. (65) Prior Publication Data Browne et al., Chapter 2. Isotope Effect: Implications for pharma US 2011/0306552 A1 Dec.
    [Show full text]
  • Pharmacotherapy for Mild Hypertension (Review) – the Cochrane Collaboration
    Pharmacotherapy for mild hypertension (Review) Diao D, Wright JM, Cundiff DK, Gueyffier F This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 11 http://www.thecochranelibrary.com Pharmacotherapy for mild hypertension (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. T A B L E O F C O N T E N T S HEADER ....................................... 1 ABSTRACT ...................................... 1 PLAIN LANGUAGE SUMMARY .............................. 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . 2 BACKGROUND .................................... 5 OBJECTIVES ..................................... 5 METHODS ...................................... 5 RESULTS ....................................... 6 Figure 1. ..................................... 7 DISCUSSION ..................................... 8 Figure 2. ..................................... 9 AUTHORS’ CONCLUSIONS ............................... 10 ACKNOWLEDGEMENTS ................................ 10 REFERENCES ..................................... 10 CHARACTERISTICS OF STUDIES ............................. 13 DATA AND ANALYSES .................................. 19 Analysis 1.1. Comparison 1 Treatment versus No Treatment, Outcome 1 Mortality. 19 Analysis 1.2. Comparison 1 Treatment versus No Treatment, Outcome 2 Stroke. 20 Analysis 1.3. Comparison 1 Treatment versus No Treatment, Outcome 3 Coronary Heart Disease. 20 Analysis 1.4. Comparison 1 Treatment versus
    [Show full text]
  • Cochrane Library
    Cochrane Library Cochrane Database of Systematic Reviews Withdrawal of antihypertensive drugs in older people (Review) Reeve E, Jordan V, Thompson W, Sawan M, Todd A, Gammie TM, Hopper I, Hilmer SN, Gnjidic D Reeve E, Jordan V, Thompson W, Sawan M, Todd A, Gammie TM, Hopper I, Hilmer SN, Gnjidic D. Withdrawal of antihypertensive drugs in older people. Cochrane Database of Systematic Reviews 2020, Issue 6. Art. No.: CD012572. DOI: 10.1002/14651858.CD012572.pub2. www.cochranelibrary.com Withdrawal of antihypertensive drugs in older people (Review) Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane Trusted evidence. Informed decisions. Library Better health. Cochrane Database of Systematic Reviews T A B L E O F C O N T E N T S HEADER......................................................................................................................................................................................................... 1 ABSTRACT..................................................................................................................................................................................................... 1 PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2 SUMMARY OF FINDINGS.............................................................................................................................................................................
    [Show full text]
  • The Pharmacological Treatment of Arterial Hypertension in Frail, Older Patients a Systematic Review
    MEDICINE Original Article The Pharmacological Treatment of Arterial Hypertension in Frail, Older Patients A Systematic Review Viktoria Mühlbauer*, Dhayana Dallmeier*, Simone Brefka, Claudia Bollig, Sebastian Voigt-Radloff, Michael Denkinger he current recommendations for blood pressure tar- Summary get values and pharmacological treatment of arterial hypertension in older people are heterogeneous (1, Background: It is debated whether the treatment goals and decision-making T 2). The 2017 guideline of the American College of Car- algorithms for elderly patients with hypertension should be the same as those for diology recommends a new target value of systolic blood younger patients. The American and European guidelines leave decisions about pressure <130 mmHg for persons ≥ 65 years living at antihypertensive treatment in frail, institutionalized patients up to the treating home (3). For the same age group, the recently published physician. We therefore systematically searched the literature for publications on guidelines of the European Society of Cardiology (ESC), the phamacotherapy of arterial hypertension in frail patients. state a target range of 130 to 139 mmHg for systolic Methods: The MEDLINE, Embase, and Central databases were systematically pressure (level of evidence A) (4). The German Hyperten- searched for randomized, controlled trials (RCTs) and non-randomized studies, sion League and the German College of General including observational studies, on the pharmacotherapy of arterial hypertension in Practitioners and Family Physicians (DEGAM) also elderly patients since the introduction of the concept of frailty, published over the recommend that the blood pressure should be period 1992–2017. <140/90 mmHg in the elderly (5–7). However, the Results: Out of 19 282 citations for randomized, controlled trials and 5659 for DEGAM describes the research data on antihypertensive non-randomized trials and observational studies, four RCTs and three observational treatment in older patients as inadequate (6).
    [Show full text]
  • Solutions Your Api Intermediates
    Price list All products SMART SOLUTIONS YOUR API INTERMEDIATES Smart Solutions GmbH Dr. Kurt - Schumacher Straße 19 90402 Nürnberg Tel.: 0911 / 211 025 0 [email protected] Preise vom 14.10.2020 All products (-)-trans-delta-9-Tetrahydrocannabinol (Dronabinol Art.Nr. BTM14904 price [USD ($)] (3,4-Methylenedioxyphenyl)-2-methylaminopropan-1-o Art.Nr. BTM14753 price [USD ($)] (Naphtalen-1-yl)(1-butyl-1H-indol-3-yl)methanon Art.Nr. BTM14780 price [USD ($)] (Naphtalen-1-yl)(1-hexyl-1H-indol-3-yl)methanon Art.Nr. BTM14781 price [USD ($)] (Naphtalen-1-yl)(1-pentyl-1H-indol-3yl)methanon Art.Nr. BTM14782 price [USD ($)] 1-(1-Phenyl-cyclohexyl)-pyrrolidin Art.Nr. BTM14856 price [USD ($)] 1-(2-Chlorphenyl)piperazin / o-Chlorphen Art.Nr. BTM14485 price [USD ($)] 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidin Art.Nr. BTM14857 price [USD ($)] 1-(3,4,5-Trimethoxyphenyl)-2-aminoethan Art.Nr. BTM14925 price [USD ($)] 1-(3-Chloropropyl)-4-methylpiperazine (CAS: 104-16 Art.Nr. 8369 price [USD ($)] (CAS: 104-16-5) 1290.00 1-(3-Chlorphenyl)piperazin / m-Chlorphen Art.Nr. BTM14486 price [USD ($)] 1-(3-Trifluoromethylphenyl)piperazin Art.Nr. BTM14920 price [USD ($)] 1-(4-Chlorphenyl)piperazin / p-Chlorphen Art.Nr. BTM14487 price [USD ($)] 1-(4-Fluorophenyl)propan-2-amin Art.Nr. BTM14639 price [USD ($)] 1-Benzylpiperazin dihydrochlorid (CAS: 5321-63-1) Art.Nr. BTM14463 price [USD ($)] 1-Hydroxy-3-(1,2-dimethylheptyl)-7,8,9,10-tetrahyd Art.Nr. BTM14656 price [USD ($)] 1-Hydroxy-3-n-hexyl-7,8,9,10-tetrahydro-6,6,9-trim Art.Nr. BTM14660 price [USD ($)] 1-Methyl-4-phenyl-4-propionoxypiperidin (MPPP) Art.Nr.
    [Show full text]